Liposomal irinotecan plus cisplatin for advanced solid tumors
This trial tests a combination of two chemotherapy drugs (liposomal irinotecan and cisplatin) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 20 and 85 years old.
- Have a confirmed solid tumor that is advanced, recurrent, or has spread and cannot be cured by surgery or local therapy.
- Have tried standard treatment that no longer works, or no standard treatment exists for your cancer.
- Have tumors that can be measured on scans (RECIST v1.1).
- Be in good physical condition (ECOG score 0 or 1) and have adequate organ function (blood counts, liver, and kidneys).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests adding liposomal irinotecan to standard chemotherapy and radiation for locally advanced esophageal squamous cell cancer. The goal is to see if this combination works better than current treatments.
This trial tests whether a liposomal form of the chemotherapy drug irinotecan can help people with advanced neuroendocrine tumors or cancers of the pancreas or gastrointestinal tract. It is designed for those who have not had prior systemic treatment or who have not received it yet.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
Hear when a new Advanced Solid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.